If approved, GSK's depemokimab will be the first ultra-long-acting biologic that requires only one dose every six months.

Shares of GSK PLC GSK inched up 0.94% to £14.01 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.28% to 8,557.81. GSK ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation ...

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

EMA accepts for review regulatory application of GSK’s Shingrix new prefilled syringe presentation for prevention of shingles: London, UK Wednesday, January 29, 2025, 13:00 Hrs ...

Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue disciplined capital allocation strategy, including sig ...

Innovations breaking barriers to children’s immunisation in Nigeria and Ethiopia win major funding from Save the Children ...

Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue ...

ShareThe year 2024 etched an indelible mark on Nigeria’s economic history as over 20 highprofile multinational corporations, including Unilever Nigeria Plc, Procter & Gamble, GlaxoSmithKline Consumer ...